|
SEC
File Number: 0-54296
|
|
CUSIP
Number: 05463V 100
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
(Check one):
[
] Form 10-Q [ ] Form 20-F [ ]
Form 11-K [X] Form 10-Q [ ] Form 10-D
[ ] Form N-SAR
For
Period Ended: June 30, 2022
[
]Transition Report on Form 10-Q
[
]Transition Report on Form 20-F
[
]Transition Report on Form 11-K
[
]Transition Report on Form 10-Q
[
]Transition Report on Form N-SAR
For
the Transition Period Ended: _______________
|
Read Instructions (on back page) Before Preparing Form.
Please Print or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates:
PART I - REGISTRANT INFORMATION
|
Full
Name of Registrant:
|
Axim Biotechnologies, Inc.
|
|
Former Name if Applicable:
|
|
|
Address of Principal
Executive Office (Street and Number):
|
6191 Cornerstone Court, E., Suite 114
|
|
City,
State and Zip Code:
|
San Diego, CA 92121
|
PART II - RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if
appropriate)
|
[
X ]
|
(a)
|
The
reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
|
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Forms 10-K, 20-F, 11-K, Form N-SAR, or Form N-CSR or portion
thereof, will be filed on or before the 15th calendar day following
the prescribed due date; or the subject quarterly report or
transition report on Form 10-Q, or portion thereof, will be filed
on or before the fifth calendar day following the prescribed due
date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
|
PART III - NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 11-K, 10-Q,
10-D, N-SAR, N-CSR or the transition report portion thereof, could
not be filed within the prescribed time period.
The Registrant
is unable to file, without unreasonable effort or expense, its
Quarterly Report on Form 10-Q for the period ended June 30, 2022
(the “Form 10-Q”). Additional time is needed for the
Registrant’s independent registered public accounting firm to
complete its review of the Registrant’s financial statements
included in the Form 10-Q and for the Registrant to provide
additional information to its accountants and auditors in order to
produce a complete, accurate Quarterly Report. Additionally, the
Registrant seeks an extension to finalize the narrative of the Form
10-Q so that it will properly inform investors and the public of
the Registrant’s actions for the period ended June 30, 2022.
The Registrant anticipates that it will file the Quarterly
Report no later than the fifth calendar day following the
prescribed filing date.
PART IV - OTHER INFORMATION
(1)Name
and telephone number of person to contact in regard to this
notification:
|
John W. Huemoeller II
|
|
(212) 332-1677
|
|
(Name)
|
|
(Area
Code) (Telephone number)
|
(2)Have
all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months (or for such
shorter) period that the registrant was required to file such
reports) been filed? If answer is no, identify
report(s): [X] Yes [
] No
(3)Is
it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject
report or portion thereof: [ ]
Yes [X] No
If
so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be
made.
|
AXIM Biotechnologies, Inc.
|
|
(Name
of Registrant as Specified in Charter)
|
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date:
August 15, 2022
|
|
/s/ John W. Huemoeller II
|
|
|
|
John W. Huemoeller II President
|
INSTRUCTION: The form may be signed by an executive officer
of the registrant or by any other duly authorized representative.
The name and title of the person signing the form shall be
typed or printed beneath the signature. If the statement is
signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative’s
authority to sign on behalf of the registrant shall be filed with
the form.